A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized phase 2 trial aiming to assess the early efficacy of two experimental
treatment sequences.
Three arms are planned; (i) standard chemotherapy followed at progression by single agent
immunotherapy with durvalumab (CT), (ii) experimental single agent immunotherapy with
durvalumab followed at progression by chemotherapy, (iii) experimental combination
immunotherapy with durvalumab+tremelimumab followed at progression by chemotherapy.
The the two experimental strategies will be compared with the standard strategy in terms of
12-month overall survival, time considered informative for the type of treatment and disease
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute, Naples
Collaborators:
AstraZeneca University of Campania "Luigi Vanvitelli"